NO882341L - Ekspresjon av humant proapolipoprotein a-i. - Google Patents

Ekspresjon av humant proapolipoprotein a-i.

Info

Publication number
NO882341L
NO882341L NO88882341A NO882341A NO882341L NO 882341 L NO882341 L NO 882341L NO 88882341 A NO88882341 A NO 88882341A NO 882341 A NO882341 A NO 882341A NO 882341 L NO882341 L NO 882341L
Authority
NO
Norway
Prior art keywords
proapolipoprotein
sequence
expression
expression vectors
humant
Prior art date
Application number
NO88882341A
Other languages
English (en)
Other versions
NO882341D0 (no
NO179253B (no
NO179253C (no
Inventor
Alex Bollen
Jean Gobert
Ernst Wuelfert
Original Assignee
Ucb Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Sa filed Critical Ucb Sa
Publication of NO882341D0 publication Critical patent/NO882341D0/no
Publication of NO882341L publication Critical patent/NO882341L/no
Publication of NO179253B publication Critical patent/NO179253B/no
Publication of NO179253C publication Critical patent/NO179253C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO882341A 1987-05-28 1988-05-27 Rekombinant DNA-sekvens som koder for humant proapolipoprotein A-I, ekspresjonsvektorer, cellekulturer samt fremgangsmåte for fremstilling av proteinet NO179253C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB878712540A GB8712540D0 (en) 1987-05-28 1987-05-28 Expression of human proapolipoprotein a-i

Publications (4)

Publication Number Publication Date
NO882341D0 NO882341D0 (no) 1988-05-27
NO882341L true NO882341L (no) 1988-11-29
NO179253B NO179253B (no) 1996-05-28
NO179253C NO179253C (no) 1996-09-04

Family

ID=10618034

Family Applications (1)

Application Number Title Priority Date Filing Date
NO882341A NO179253C (no) 1987-05-28 1988-05-27 Rekombinant DNA-sekvens som koder for humant proapolipoprotein A-I, ekspresjonsvektorer, cellekulturer samt fremgangsmåte for fremstilling av proteinet

Country Status (33)

Country Link
US (1) US5059528A (no)
EP (1) EP0293357B1 (no)
JP (1) JP2634193B2 (no)
KR (1) KR970000808B1 (no)
CN (1) CN1031892C (no)
AT (1) ATE89006T1 (no)
AU (1) AU615654B2 (no)
CA (1) CA1323851C (no)
CY (1) CY1809A (no)
CZ (1) CZ283648B6 (no)
DD (1) DD291093A5 (no)
DE (1) DE3880739T2 (no)
DK (1) DK175686B1 (no)
EG (1) EG19101A (no)
ES (1) ES2054878T3 (no)
FI (1) FI100056B (no)
GB (1) GB8712540D0 (no)
HK (1) HK137794A (no)
HU (1) HU204562B (no)
IE (1) IE62422B1 (no)
IL (1) IL86480A (no)
LT (1) LT3600B (no)
LV (1) LV5288A3 (no)
NO (1) NO179253C (no)
NZ (1) NZ224808A (no)
PL (1) PL158064B1 (no)
PT (1) PT87562B (no)
RU (1) RU2009198C1 (no)
SG (1) SG131594G (no)
SK (1) SK279166B6 (no)
SU (1) SU1834904A3 (no)
UA (1) UA19765A (no)
ZA (1) ZA883824B (no)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU587989B2 (en) * 1984-10-16 1989-09-07 Mitsubishi Chemical Corporation DMA fragments, expression vectors, proteins, hosts, and process for production of the proteins
JP2606228B2 (ja) * 1987-09-18 1997-04-30 三菱化学株式会社 ヒトプロアポリポプロテインａ−ｉ様蛋白の産生法
EP0345155B1 (en) * 1988-05-31 1994-08-10 Mitsubishi Kasei Corporation Process for producing natural human apolipoprotein e-like proteins
US5846799A (en) * 1988-06-14 1998-12-08 La Region Wallone Human myeloperoxidase and its therapeutic application
US5460961A (en) * 1988-06-14 1995-10-24 La Region Wallonne Human myeloperoxidase and its therapeutic application
IT1229996B (it) * 1989-04-20 1991-09-20 Cesare Sirtori Espressione di apolipoproteina ai e apolipoproteina ai-milano in lievito e composizioni farmaceutiche che contengono dette apolipoproteine.
DK0574402T3 (da) * 1990-11-26 1998-05-18 Chiron Corp Ekspression af PACE i værtsceller og fremgangsmåder til anvendelse deraf
WO1992010760A1 (en) * 1990-11-30 1992-06-25 Monoclonetics International, Incorporated Methods for the diagnosis of chronic lower back and cervical pain
US5844097A (en) * 1990-11-30 1998-12-01 Monoclonetics International, Inc. Methods for the diagnosis of peripheral nerve damage
SE9500778D0 (sv) 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
US5994061A (en) * 1995-09-29 1999-11-30 Queen's University At Kingston DNA constructs and methods for screening for increased expression of human apo AI gene
SE9603068D0 (sv) 1996-08-23 1996-08-23 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603304D0 (sv) 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a compound
SE9603303D0 (sv) 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a protein
KR100330355B1 (ko) * 1999-06-04 2002-04-01 장인순 회전유동발생 날개를 가진 덕트형 핵연료 집합체 지지격자
US6579710B2 (en) * 2000-12-12 2003-06-17 Lexicon Genetics Incorporated Human kinases and polynucleotides encoding the same
US20040047853A1 (en) * 2000-06-09 2004-03-11 Dahl Soren W Purified proenzyme of dipeptidyl peptidase i (pro-dppi)
KR100560102B1 (ko) * 2004-06-25 2006-03-13 한국생명공학연구원 프로아포리포단백질 ａ－ⅰ 변이체와, 이를 포함하는고지혈증 또는 동맥경화증 예방 및 치료제
US7427662B2 (en) * 2005-02-01 2008-09-23 Baord Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Inhibition of angiogenesis and destruction of angiogenic vessels by apolipoprotein A-I and high density lipoprotein
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
US20070048823A1 (en) * 2005-08-26 2007-03-01 Cerenis Therapeutics, S.A. Compositions and Methods for Producing Apolipoprotein Gene Products in Lactic Acid Bacteria
US20080293102A1 (en) * 2007-02-28 2008-11-27 Cerenis Therapeutics Holding, S.A. Compositions and methods for producing apolipoprotein
EP2352830B1 (en) * 2008-10-03 2019-01-16 CuRNA, Inc. Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoprotein-a1
KR102042721B1 (ko) 2008-11-10 2019-11-11 알닐람 파마슈티칼스 인코포레이티드 치료제 운반용 신규 지질 및 조성물
EP2391343B1 (en) 2009-01-29 2017-03-01 Arbutus Biopharma Corporation Improved lipid formulation for the delivery of nucleic acids
CA2754043A1 (en) 2009-03-12 2010-09-16 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes
CA3042927C (en) 2009-05-05 2022-05-17 Arbutus Biopharma Corporation Lipid compositions for the delivery of therapeutic agents
WO2010129799A2 (en) 2009-05-06 2010-11-11 Curna, Inc. Treatment of lipid transport and metabolism gene related diseases by inhibition of natural antisense transcript to a lipid transport and metabolism gene
KR20230098713A (ko) 2009-06-10 2023-07-04 알닐람 파마슈티칼스 인코포레이티드 향상된 지질 조성물
EP2810643A3 (en) 2009-08-14 2015-03-11 Alnylam Pharmaceuticals Inc. Lipid formulated compositions and mehods for inhibiting expression of a gene from the ebola virus
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
US10525152B2 (en) 2009-10-09 2020-01-07 Signablok, Inc. Methods and compositions for targeted imaging
EP3296398A1 (en) 2009-12-07 2018-03-21 Arbutus Biopharma Corporation Compositions for nucleic acid delivery
WO2011075656A1 (en) 2009-12-18 2011-06-23 The University Of British Columbia Methods and compositions for delivery of nucleic acids
US20130156845A1 (en) 2010-04-29 2013-06-20 Alnylam Pharmaceuticals, Inc. Lipid formulated single stranded rna
US20130137628A1 (en) 2010-05-11 2013-05-30 Esperion Therapeutics, Inc. Dimeric Oxidation-Resistant Apolipoprotein A1 Variants
EP2575764B1 (en) 2010-06-03 2017-04-19 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
US20130323269A1 (en) 2010-07-30 2013-12-05 Muthiah Manoharan Methods and compositions for delivery of active agents
US20130202652A1 (en) 2010-07-30 2013-08-08 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
WO2012064824A1 (en) 2010-11-09 2012-05-18 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes
DK3202760T3 (da) 2011-01-11 2019-11-25 Alnylam Pharmaceuticals Inc Pegylerede lipider og deres anvendelse til lægemiddelfremføring
PL2767546T3 (pl) 2011-02-07 2019-04-30 Cerenis Therapeutics Holding Sa Kompleksy lipoproteinowe i ich wytwarzanie oraz ich zastosowania
JP6250543B2 (ja) 2011-09-27 2017-12-20 アルニラム・ファーマシューティカルズ・インコーポレーテッド ジ脂肪族置換ｐｅｇ化脂質
US9610324B2 (en) * 2012-07-11 2017-04-04 Esperion Therapeutics, Inc. Apolipoprotein mixtures
AU2014259759B2 (en) * 2013-05-01 2020-06-18 Ionis Pharmaceuticals, Inc. Compositions and methods
EP2853259A1 (en) 2013-09-30 2015-04-01 Université Pierre et Marie Curie (Paris 6) Reconstituted high density lipoproteins composition and uses thereof
US20150316566A1 (en) 2014-05-02 2015-11-05 Cerenis Therapeutics Holding Sa Hdl therapy markers
EP3533872A4 (en) * 2016-10-27 2020-09-09 Institute Of Microbiology, Chinese Academy Of Sciences PROCESS FOR MODIFYING AN AMINO ACID ATTENUATOR AND ITS USE IN PRODUCTION
WO2019030574A1 (en) 2017-08-10 2019-02-14 Cerenis Therapeutics Holding CARGOMÈRES
WO2019030575A1 (en) 2017-08-10 2019-02-14 Cerenis Therapeutics Holding APOMÈRES
US11081113B2 (en) 2018-08-24 2021-08-03 Bright Marbles, Inc. Idea scoring for creativity tool selection
US11189267B2 (en) 2018-08-24 2021-11-30 Bright Marbles, Inc. Intelligence-driven virtual assistant for automated idea documentation
US11164065B2 (en) 2018-08-24 2021-11-02 Bright Marbles, Inc. Ideation virtual assistant tools
US11461863B2 (en) 2018-08-24 2022-10-04 Bright Marbles, Inc. Idea assessment and landscape mapping
AU2021256086A1 (en) 2020-04-16 2022-12-15 Abionyx Pharma Sa Methods for treating acute conditions using lipid binding protein- based complexes
IL301769A (en) 2020-10-01 2023-05-01 Abionyx Pharma Sa Methods for treating eye diseases by using complexes based on lipid-binding proteins
WO2022219413A1 (en) 2021-04-15 2022-10-20 Abionyx Pharma Sa Use of lipid binding protein-based complexes in organ preservation solutions
WO2023194797A1 (en) 2022-04-06 2023-10-12 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
WO2023194798A1 (en) 2022-04-06 2023-10-12 Abionyx Pharma Sa Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes
WO2023237935A2 (en) 2022-06-10 2023-12-14 Abionyx Pharma Sa Methods for treating acute conditions using lipid binding protein-based complexes
WO2023237927A2 (en) 2022-06-10 2023-12-14 Abionyx Pharma Sa Methods for treating hyperinflammatory conditions using lipid binding protein -based complexes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU587989B2 (en) * 1984-10-16 1989-09-07 Mitsubishi Chemical Corporation DMA fragments, expression vectors, proteins, hosts, and process for production of the proteins
JPS6198998A (ja) 1984-10-18 1986-05-17 Matsushita Electric Ind Co Ltd 電動送風機
BE901119A (fr) 1984-11-23 1985-03-15 Wallone Region Procede de preparation de plasmides vecteurs capables de transformer un hote bacterien escherichia coli et d'y promouvoir et controler l'expression d'un adn heterologue.
WO1986004920A1 (en) 1985-02-13 1986-08-28 Biotechnology Research Partners, Limited Human metallothionein-ii promoter in mammalian expression system
GB8507833D0 (en) * 1985-03-26 1985-05-01 Biogen Nv Production of human somatomedin c
EP0239631A4 (en) 1985-10-04 1989-01-12 Biotech Res Partners Ltd RECOMBINANT APOLIPOPROTEINS AND METHODS.
GB8625435D0 (en) * 1986-10-23 1986-11-26 Erba Farmitalia Human apolipoprotein ai
WO1988003175A1 (en) * 1986-10-29 1988-05-05 Biotechnology Research Partners, Ltd. Apoai-ciii-aiv, apoaii, apob, apoci, and ldl receptor polymorphisms for genetic fingerprinting and predictive of atherosclerosis

Also Published As

Publication number Publication date
FI100056B (fi) 1997-09-15
KR970000808B1 (en) 1997-01-20
LT3600B (en) 1995-12-27
FI882456A0 (fi) 1988-05-25
SK363888A3 (en) 1998-07-08
EP0293357B1 (fr) 1993-05-05
HU204562B (en) 1992-01-28
CN88103118A (zh) 1988-12-14
CY1809A (en) 1995-10-20
SU1834904A3 (ru) 1993-08-15
ZA883824B (en) 1989-02-22
RU2009198C1 (ru) 1994-03-15
PT87562B (pt) 1992-09-30
UA19765A (uk) 1997-12-25
CA1323851C (en) 1993-11-02
PL272698A1 (en) 1989-03-06
NZ224808A (en) 1990-01-29
LTIP828A (en) 1995-02-27
EG19101A (en) 1994-09-29
IE881597L (en) 1988-11-28
CZ363888A3 (cs) 1998-02-18
JPS6416589A (en) 1989-01-20
LV5288A3 (lv) 1993-10-10
DE3880739D1 (de) 1993-06-09
FI882456A (fi) 1988-11-29
EP0293357A1 (fr) 1988-11-30
PL158064B1 (pl) 1992-07-31
HUT47153A (en) 1989-01-30
US5059528A (en) 1991-10-22
CN1031892C (zh) 1996-05-29
NO882341D0 (no) 1988-05-27
DD291093A5 (de) 1991-06-20
AU1672388A (en) 1988-12-01
DE3880739T2 (de) 1993-08-19
DK289688A (da) 1988-11-29
IL86480A (en) 1992-08-18
ATE89006T1 (de) 1993-05-15
NO179253B (no) 1996-05-28
PT87562A (pt) 1989-05-31
DK175686B1 (da) 2005-01-17
SG131594G (en) 1995-01-13
IE62422B1 (en) 1995-02-08
NO179253C (no) 1996-09-04
HK137794A (en) 1994-12-16
IL86480A0 (en) 1988-11-15
DK289688D0 (da) 1988-05-27
GB8712540D0 (en) 1987-07-01
CZ283648B6 (cs) 1998-05-13
KR880014110A (ko) 1988-12-22
SK279166B6 (sk) 1998-07-08
AU615654B2 (en) 1991-10-10
JP2634193B2 (ja) 1997-07-23
ES2054878T3 (es) 1994-08-16

Similar Documents

Publication Publication Date Title
NO882341L (no) Ekspresjon av humant proapolipoprotein a-i.
NO177570B (no) Fremgangsmåte ved fremstilling av peptider med fibronektinbindende egenskaper, mikroorganisme og DNA-sekvens som koder for peptider med fibronektinbindende egenskaper
FI961202A0 (fi) Grb3-3-geeni, sen variantteja ja niiden käyttöjä
NO930428L (no) Proteinstrukturen til plantetoksingelonin
ATE166390T1 (de) Anti-katze immundefiziensvirus (fiv) impfstoffe
DK595187D0 (da) Minactivin og fremgangsmaade til fremstilling deraf
ATE188997T1 (de) Klonierung von malaria-spezifischen dna- sequenzen:isolierung des gens für das 140 kd protein
DE69636737D1 (de) Neues immunoregulatorisches protein lst-1
TH5997EX (th) การสร้างโปรอโปดิโปรโปรตีน a-i ของคนโดยการแสดงออกของรหัสพันธุกรรม

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees